Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Researchers At The University Of Tennessee Health Science Center Begin New Study On Parkinson's Disease
Researchers at the University of Tennessee Health Science Center (UTHSC) are recruiting participants for a national clinical study of medication that could slow the progression of Parkinson"s disease. The study, referred to as "QE3," will examine the effectiveness of the research medication Coenzyme Q10 (CoQ). During the study, investigators will administer high doses of CoQ to participants 30 years of age or older with early stage Parkinson"s disease to reduce the speed of their physical decline. The research is sponsored by the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health (NIH), and will be conducted by the Parkinson Study Group, an international council of physicians and researchers experienced in caring for Parkinson"s patients and studying the disease.
generic viagra online
Stem Cell Transplant In Mouse Embryo Yields Heart Protection In Adulthood
Stem cells play a role in heart muscle rejuvenation by attracting cells from the body that develop into heart muscle cells. They have been successfully used to halt or reverse cardiac injury following heart attack, but not to prevent injury before it occurs.
News of the day
Access To Abortion Services In Kansas Hindered After Closure Of Tiller's Clinic
After the murder of abortion provider George Tiller and the closure of his Wichita, Kan., clinic, residents of the city face about a three-hour drive to the nearest abortion provider, a distance experts say is not uncommon for access to abortion services in southern and midwestern states, the Wichita Eagle reports. Jenny O"Donnell of the Abortion Access Project said that southern and midwestern states have the heaviest restrictions on abortion, adding that "substantial populations don"t have an abortion provider" in states such as Mississippi and Arkansas. According to 2005 statistics from the Guttmacher Institute, 87% of U.S. counties have no abortion provider; the figure rises to 94% of counties in the Midwest and 96% of counties in Kansas. The number of abortion providers in Kansas declined from 15 in 1992 to seven in 2005, while the number of providers nationwide dropped from 2,380 to 1,787 over the same time period, according to Guttmacher. Experts say the decline is the result of several factors, including public pressures, increased regulation that has driven up the cost and complexity of providing abortion and a general trend in the health care industry toward consolidated, more specialized practices.Vicki Saporta, president and CEO of the National Abortion Federation, said that the decrease in the number of abortion providers is misleading on some levels. The decline primarily has occurred among hospitals and small providers who perform a few procedures a year, while major clinics that specialize in abortion have remained essentially stable, Saporta said. Peter Brownie, executive director of Planned Parenthood of Kansas and Mid-Missouri, said that the group"s clinics have experienced an increase in contacts from women from south-central Kansas since Tiller"s clinic closed a little more than one week ago. He added, "At the present time, there"s no place between Denver and Kansas City where a woman can obtain abortion care. That"s a significant barrier for women throughout the state that have that need." NAF has established a national hotline to offer referrals for women who have to make new arrangements for abortion care because of the closure of Tiller"s clinic, Saporta said (Lefler, Wichita Eagle, 6/9).
Oncology

Scientists Open The Door To Future 2-in-1 Breast Cancer Treatments

Scientists from the Breakthrough Breast Cancer Research Centre based at the Institute of Cancer Research have shown for the first time that it is possible for one drug to simultaneously attack cancer cells in two completely different ways. Researchers now hope this discovery could lead to further two-in-one treatments - meaning breast cancer patients could potentially need to take fewer drugs to treat tumours in the future. The laboratory study led by Prof Mitch Dowsett and Dr Lesley-Ann Martin was funded by Avon Cosmetics, The Mary-Jean Mitchell Green Foundation and Novartis Pharma in a joint venture and is published in the current issue of Cancer Research. The team showed that an experimental compound called PTK/ZK, originally developed as an "angiogenesis inhibitor" to block a tumour"s blood supply and slow its growth, also acted as an "aromatase inhibitor". In this way it prevents the growth of hormone sensitive breast cancers reliant on oestrogen for their growth and survival. This type of breast cancer accounts for over 70% of all cases of breast cancer. Scientists from Breakthrough and Novartis used advanced computer modelling to demonstrate that the shape of PTK/ZK allows it to block aromatase and prevent it working. Dr Susana Banerjee, a member of the team, said: "We found one compound could launch a two-pronged attack on some cancer cells. Although the drug we researched, PTK/ZK, is no longer in development, this unique discovery raises the very exciting possibility that we might be able to intentionally engineer drugs to target two distinct biological pathways in the future. "Developing one drug that attacks a tumour in two completely different ways may provide a better approach to fighting breast cancer. Not only does this approach have the potential to boost the effectiveness of existing drugs, it could also mean that patients need to take fewer drugs to treat tumours." Dr Susana Banerjee is one of four clinicians sponsored by Avon Cosmetics to carry out research at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London. Part of Avon"s ongoing commitment to tackling the disease, all "Dr Avons" are funded for three years through Avon"s Breast Cancer Crusade Programme - the only such initiative in the UK to be funded by a beauty company. The programme supports individuals working on research which focuses on developing results from the laboratory into better ways to diagnose and treat patients as quickly as possible. Avon has raised over ÷£14million for Breakthrough Breast Cancer since the Avon Crusade began 17 years ago. - PTK/ZK is a Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor - The research was carried out by a team led by Prof Mitch Dowsett and Dr Lesley-Ann Martin at the Breakthrough Toby Robins Breast Cancer Research Centre - the UK"s first facility dedicated to research into prevention and treatment of the disease. It is housed in the Mary-Jean Mitchell Green Building, at The Institute of Cancer Research and benefits from close links with The Royal Marsden Hospital next door. Avon Cosmetics - Avon has supported Breakthrough Breast Cancer for 17 years in the form of the Avon Breast Cancer Crusade. Thanks to associates, customers and sales Representatives in the UK, Avon has raised more than ÷£14 million for Breakthrough Breast Cancer, largely through sales of special fundraising products and employee fundraising activities. - Avon is Breakthrough Breast Cancer"s longest-standing corporate partner. Avon Cosmetics is the world"s leading direct seller of beauty and related products, with a global annual turnover of $10 billion. Avon markets to women in over 100 countries through 5.4 million independent sales Representatives. Visit http://www.avon.uk.com for more information. Breakthrough Breast Cancer - Breakthrough Breast Cancer is the UK"s leading breast cancer charity committed to fighting breast cancer through research, campaigning and education. In 1999 Breakthrough established the UK"s first dedicated breast cancer research centre. The Breakthrough Toby Robins Breast Cancer Research Centre is housed in the Mary-Jean Mitchell Green building at The Institute of Cancer Research and was set up in association with the Royal Marsden Hospital. The Institute of Cancer Research - The Institute of Cancer Research is Europe"s leading cancer research centre with expert scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care. Website at: www.icr.ac.uk. - The Institute is a charity that relies on voluntary income. The Institute is one of the world"s most cost-effective major cancer research organisations with over 95p in every pound of total income directly supporting research. Institute of Cancer Research


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009